GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Capex-to-Revenue

Biolife Sciences (Biolife Sciences) Capex-to-Revenue : 0.00 (As of May. 2008)


View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Biolife Sciences's Capital Expenditure for the three months ended in May. 2008 was $0.00 Mil. Its Revenue for the three months ended in May. 2008 was $1.80 Mil.

Hence, Biolife Sciences's Capex-to-Revenue for the three months ended in May. 2008 was 0.00.


Biolife Sciences Capex-to-Revenue Historical Data

The historical data trend for Biolife Sciences's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences Capex-to-Revenue Chart

Biolife Sciences Annual Data
Trend Nov04 Nov05 Nov06 Nov07
Capex-to-Revenue
- - - -

Biolife Sciences Quarterly Data
Nov04 Feb05 May05 Aug05 Nov05 Feb06 May06 Aug06 Nov06 Feb07 May07 Aug07 Nov07 Feb08 May08
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biolife Sciences's Capex-to-Revenue

For the Medical Instruments & Supplies subindustry, Biolife Sciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolife Sciences's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolife Sciences's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biolife Sciences's Capex-to-Revenue falls into.



Biolife Sciences Capex-to-Revenue Calculation

Biolife Sciences's Capex-to-Revenue for the fiscal year that ended in Nov. 2007 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 8.603
=0.00

Biolife Sciences's Capex-to-Revenue for the quarter that ended in May. 2008 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 1.798
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biolife Sciences  (OTCPK:BLFE) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Biolife Sciences Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolife Sciences (Biolife Sciences) Business Description

Traded in Other Exchanges
N/A
Address
2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052
Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.
Executives
Arthur Viola director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired 09-15-2020